Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib
Status:
Completed
Trial end date:
2013-06-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the mass balance (i.e. cumulative excretion of total
radioactivity [TRA] in urine and feces) of alisertib and pharmacokinetic (PK) of alisertib in
plasma and urine, and of TRA in plasma and whole blood.